Cargando…
Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience
Botulinum toxin type A is one of the most useful treatments of sialorrhea in neurological disorders. Evidence for the use of incobotulinumtoxin A (inco-A) in the treatment of sialorrhea is limited. Thirty-six patients with sialorrhea were treated with infiltrations of inco-A into both parotid glands...
Autores principales: | Martínez-Poles, Javier, Nedkova-Hristova, Velina, Escribano-Paredes, José Bernardo, García-Madrona, Sebastián, Natera-Villalba, Elena, Estévez-Fraga, Carlos, López-Sendón Moreno, José Luis, Avilés-Olmos, Icíar, Sánchez Díaz, Gema, Martínez Castrillo, Juan Carlos, Alonso-Canovas, Araceli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024805/ https://www.ncbi.nlm.nih.gov/pubmed/29843420 http://dx.doi.org/10.3390/toxins10060217 |
Ejemplares similares
-
Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI
por: Berweck, Steffen, et al.
Publicado: (2021) -
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
por: Jost, Wolfgang H., et al.
Publicado: (2019) -
Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions
por: Makino, Koji, et al.
Publicado: (2020) -
Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis
por: Berweck, Steffen, et al.
Publicado: (2022) -
Impulse Control Disorders in Parkinson's Disease: Has COVID‐19 Related Lockdown Been a Trigger?
por: Rábano‐Suárez, Pablo, et al.
Publicado: (2021)